Longitudinal analysis of circulating tumor cell numbers improves tracking metastatic breast cancer progression

Malgorzata Szostakowska-Rodzos,Anna Fabisiewicz,Maciej Wakula,Sylwia Tabor,Lukasz Szafron,Agnieszka Jagiello-Gruszfeld,Ewa Anna Grzybowska
DOI: https://doi.org/10.1038/s41598-024-63679-4
IF: 4.6
2024-06-07
Scientific Reports
Abstract:Hormone-responsive breast cancer represents the most common type and has the best prognosis, but still approximately 40% of patients with this type can develop distant metastases, dramatically worsening the patient's survival. Monitoring metastatic breast cancer (mBC) for signs of progression is an important part of disease management. Circulating tumor cell (CTC) detection and molecular characteristics gain importance as a diagnostic tool, but do not represent a clinical standard and its value as a predictor of progression is not yet established. The main objective of this study was to estimate the prognostic value of not only the CTC numbers, but also the dynamics of the CTC numbers in the same patient during the continuous evaluation of CTCs in patients with advanced breast cancer. The other objective was to assess the molecular changes in CTCs compared to primary tumor samples by genetic analysis of the seven genes associated with estrogen signaling pathway, mutations in which are often responsible for the resistance to endocrine therapy, and subsequent progression. This approach was taken to evaluate if genetic analysis of CTCs can be used in tracking the resistance, signaling that hormonal therapy should be replaced. Consequently, this report presents the results of a longitudinal CTC study based on three subsequent blood collections from 135 patients with metastatic breast cancer, followed by molecular analysis of the isolated single CTCs. CTCs were detected and isolated using an image-based, EpCAM-independent system CytoTrack; this approach allowed evaluation of EpCAM expression in detected CTCs. Isolated CTCs were subjected to NGS analysis to assess mutational changes. The results confirm the importance of the status of the CTC for progression-free survival and overall survival and provide new data on the dynamics of the CTC during a long monitoring period and in relation to clinical progression, highlighting the advantage of constant monitoring over the single count of CTC. Furthermore, high genetic and phenotypic inter- and intrapatient heterogeneity observed in CTCs suggest that metastatic lesions are divergent. High genetic heterogeneity in the matching CTC/primary tumor samples may indicate early dissemination. The tendency towards the accumulation of activating/oncogenic mutation in CTCs, leading to anti-estrogen resistant disease, was not confirmed in this study.
multidisciplinary sciences
What problem does this paper attempt to address?
The problems that this paper attempts to solve mainly focus on the following aspects: 1. **Evaluating the prognostic value of the number of circulating tumor cells (CTCs) and their dynamic changes in patients with metastatic breast cancer (mBC)**: - The research focuses not only on the number of CTCs, but also specifically on the dynamic changes of the CTC number in continuous monitoring to evaluate its value as an indicator for predicting disease progression. 2. **Evaluating the changes in molecular characteristics of CTCs**: - Through genetic analysis, the molecular differences between CTCs and primary tumor samples are studied, especially the mutation status of seven genes related to the estrogen signaling pathway. These mutations often lead to resistance to endocrine therapy and thus affect disease progression. 3. **Verifying whether gene analysis of CTCs can be used to track resistance to endocrine therapy**: - The research aims to determine whether gene analysis of CTCs can be used as a monitoring method to timely detect resistance to endocrine therapy, thereby suggesting a change in the treatment plan. Specifically, this study analyzed three consecutive blood samples from 135 patients with metastatic breast cancer, detected and isolated CTCs, and then performed next - generation sequencing (NGS) analysis on individual CTCs to evaluate their mutation status. The research results confirmed the prognostic value of the CTC number (especially ≥5 CTCs) in terms of progression - free survival (PFS) and overall survival (OS), and emphasized the importance of continuous monitoring of the CTC number. In addition, the study also revealed the high phenotypic and genetic heterogeneity of CTCs and the differences in this heterogeneity among different patients.